Euro: Political risk weighs but downside seen limited – ABN AMRO
ABN AMRO strategist Georgette Boele notes that changes in interest rate spreads have encouraged speculative short Euro positions, while fiscal and political uncertainty in France and Spain has historically coincided with Euro (EUR) weakness versus the US Dollar (USD). Boele argues that much of this risk is already priced into French spreads and expects sentiment and EUR/USD to remain negative near term but without a continued sell-off.
Fiscal and political uncertainty hit euro
"Changes in interest rate spreads have encouraged speculative investors to take short euro and long dollar positions."
"The euro tends to weaken when government bond yields in a major eurozone country, or in several countries, rise sharply because of political and/or fiscal concerns. There was to some fear of contagion, and this impacts the currency as well."
"This suggests that periods of fiscal and political uncertainty in the eurozone often coincide with speculators holding net short euro positions and a lower EUR/USD. The graph below on the right shows the recent relationship between the ten-year French-German government bond spread and the euro."
"In last week’s FX Weekly, we said that political uncertainty would weigh on the euro towards the end of this year and in the first quarter of next year. This pressure has emerged sooner than we expected."
"For EUR/USD, sentiment may remain negative in the near term, but we do not expect the sell-off to continue. We therefore keep our end-2026 forecast unchanged at 1.15."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Halozyme shares rise after winning a case against Merck's injectable Keytruda in a Dutch court
October 7 – Halozyme (HALO.O) shares rose 1.4% pre-market to $111.24. Halozyme announced it had obtained an injunction from a Dutch court (link), prohibiting Merck MRK.N from manufacturing, selling, and importing subcutaneous Keytruda in eight European markets. The court determined that Merck had infringed Halozyme’s EP622 patent and rejected Merck’s claims that the patent was invalid. Halozyme stated that patients will still have access to the intravenous version of Keytruda, which is not affected by the injunction. As of the close of the previous trading day, HALO shares have risen 62% this year. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to possible errors or missing context in automated translations, Reuters does not guarantee the accuracy of such translated texts, which are provided for readers’ convenience only. Reuters assumes no liability for any damages or losses caused by use of the automated translation function.)
BUZZ-KeyBanc upgrades Corteva rating to "Overweight"; stock price rises
On October 7, KeyBanc upgraded the rating of agricultural technology company Corteva Inc (CTVA.N) from "Sector Weight" to "Overweight." CTVA rose 1.6% in pre-market trading to $14.1. The brokerage pointed out that new product launches, cost reductions, and improvements in farmers' economic conditions will be strong growth drivers for 2028-2029. The company’s ample cash reserves enable it to flexibly fund growth initiatives, stock buybacks, and potential acquisitions. Out of 23 brokerages, 16 have given the stock a "Buy" or higher rating, and 7 have rated it "Hold." The median target price is $18. As of the previous trading day's close, the stock had gained 38.3% year to date.
Antofagasta’s Centinela strike adds copper supply risk
Elon Musk personally defines Terafab: TSMC can at most "sublease a portion," operation is out of the question.
Musk clarified that Terafab will be independently constructed and operated, with TSMC possibly subleasing part of the site; Intel will be involved in technology development and will supply Tesla and SpaceX AI.
Crypto prices
More
